Clinical trial · Interventional
Maintenance Hormonal Therapy and DLBCL
Effect of Maintenance Hormonal Therapy on the Outcome of Patients With DLBCL
NCT06355401CI-TRIAL-00075829not yet recruitingPhase 2 / Phase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
the study aims to detect the benefit of maintenance tamoxifen after achieving CR with conventional immuno-chemotherapy and/or radiotherapy in patients with DLDCL
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Diffuse Large B Cell Lymphoma | Diffuse Large B-Cell Lymphoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Tamoxifen 20mg | Drug | Tamoxifen | ALIAS |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- group A
- description
- DLBCL patients who achieve CR
- interventionNames
- Drug: Tamoxifen 20mg
- type
- NO_INTERVENTION
- label
- group B
- description
- DLBCL patients who achieve CR will be under follow up only
Primary outcomes (2)
- measure
- disease free survival
- timeFrame
- 2-5 years
- description
- the period from CR till 1st relapse
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: adults 18-75 years old newly diagnosed DLBCL patients who achieve CR after conventional primary treatment can be included PS 0-2 Exclusion Criteria: less than 18 years or older than 75 years other types of lymphoid neoplasms cardiac comorbidity
References
Publications (0)
Data not yet available
No reference posted for this study.